Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (712)	7/1/2003 1:06:42 PM
From: Icebrg	Read Replies (1) \| Respond to of 2240

>>Doesn't sound like good news to me.>> Funny, that we are looking at this in a completely different way. It is of course not possible for us to guess what concessions that were made by Genmab with regard to the terms. I don't think we shall be too sorry, that they will not be able to co-promote, as they don't have the organization to do so. And it is better that they devote their dwindling resources to projects where their equity stake is higher. They were always going to lose this drug if the results were good. Looking at the brighter side of the matter. It would have been much worse if they had to push the project all the way through phase II just to be told (or find out themselves) that it doesn't have any merit. Now, they should be able to collect very decent milestones as the project progresses. Something that will no doubt help with their finances. (For Medarex it is of course an advantage that Genmab finances itself through this type of deals than from equity issues). Companies of Genmab's type and size are in the business to develop projects and then to sell them to big pharma. They have just been able to sell one of these projects. That's why I fell the news were good. Erik